Asciminib is the first-in-class allosteric inhibitor that specifically binds the BCR::ABL1 myristoyl pocket used to treat patients with Chronic Myeloid Leukemia (CML). The global incidence rate of CML ...
New research shows hydroxyurea reshapes DNA replication in cancer cells, revealing stress responses that may help design ...
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today reported its business ...
Findings indicate small increases in certain cancers linked to assisted reproduction, though overall cancer incidence aligns ...
James Dentzer, President and CEO, stated that "we continue to make steady progress in our TakeAim Lymphoma study in primary CNS lymphoma, one of the most rare and most difficult to treat of the NHL ...
Crossbow Therapeutics, Inc., a biotechnology company developing a novel class of potent and precise antibody therapies to treat ...
This is the only assay available on the market that delivers full quantification of all four clinically relevant BCR::ABL1 isoformsNEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Specialty cancer ...
Excalipoint Therapeutics closed an oversubscribed $68.7 million seed financing, one of the largest early-stage rounds for a Chinese biotechnology company, to advance its pipeline of six T-cell engager ...
BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the design and ...
Xspray Pharma AB (publ) has re-submitted its application for market approval for Dasynoc® to the U.S. Food and Drug Administration (FDA). Dasynoc® is the company's lead product candidate - an amorphou ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results